亚太药业盐酸地尔硫片一致性评价申请不予批准

Core Points - The company, Asia-Pacific Pharmaceutical (002370), received a notification from the National Medical Products Administration stating that its application for the consistency evaluation of Diltiazem Hydrochloride Tablets was not approved [2] - The reason for the disapproval was that the bioequivalence study submitted could not support a conclusion of bioequivalence [2] - The company plans to improve the relevant experimental research for the drug and will reapply for approval in the future [2] Company Impact - The disapproval of Diltiazem Hydrochloride Tablets is not expected to have a significant impact on the company's current performance [2]